Rock Creek Pharmaceuticals Inc is a United States-based pharmaceutical development company. The Company is focused on the discovery, development and commercialization of therapies for chronic inflammatory disease and neurologic disorders. Its activities are focused on its lead compound, anatabine citrate (anatabine). Anatabine is a small molecule, cholinergic agonist, which exhibits anti-inflammatory pharmacological characteristics. The Company focuses on dermatological skin diseases, such as psoriasis, eczema and rare or orphan skin disorders, using its formulations of anatabine.

Employees

Sector

Pharmaceuticals

More about the company

Delayed OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

20-12-07	Rock Creek Pharmaceuticals, Inc. Went Out of Business	CI
20-02-05	Bankruptcy Judge Changed for Rock Creek Pharmaceuticals, Inc.	CI

Market Cap	153K 135K 127K 116K 217K 14.7M 218K 1.52M 589K 7.51M 576K 563K 24.14M	P/E 2014	-0.87x	P/E 2015	-1.04x
Enterprise Value	20.01M 17.56M 16.58M 15.11M 28.29M 1.92B 28.49M 198M 76.86M 980M 75.13M 73.51M 3.15B	EV / Sales 2014	-	EV / Sales 2015	-
Free-Float	100%	Yield 2014 *	-	Yield 2015	-

20-12-07	Rock Creek Pharmaceuticals, Inc. Went Out of Business	CI
20-02-05	Bankruptcy Judge Changed for Rock Creek Pharmaceuticals, Inc.	CI
18-12-20	Motion for Asset Sale Filed by Rock Creek Pharmaceuticals, Inc.	CI
18-01-10	Motion for Asset Sale Approved for Rock Creek Pharmaceuticals, Inc.	CI
16-09-27	Rock Creek Pharmaceuticals, Inc. Filed for Bankruptcy	CI
16-08-29	Rock Creek Pharmaceuticals, Inc. Receives Event of Default Redemption Notice from Hudson Bay Master Fund Ltd. and from Tenor Capital Management on Behalf of Alto Opportunity Master Fund	CI
16-08-10	Rock Creek Pharmaceuticals, Inc. Announces Earnings Results for the Second Quarter Ended June 30, 2016	CI
16-07-08	Rock Creek Pharmaceuticals, Inc. Announces Board Changes	CI
16-06-08	Rock Creek Pharmaceuticals, Inc. Reports Earnings results for the First Quarter Ended March 31, 2016	CI
16-03-29	Rock Creek Pharmaceuticals, Inc. announced that it has received $0.5 million in funding.	CI
16-03-22	Rock Creek Pharmaceuticals, Inc. Announces Earnings Results for the Year Ended December 31, 2015	CI
16-03-21	Rock Creek Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
15-11-19	Rock Creek Pharmaceuticals, Inc. Appoints Robert Scannell as Director	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ROCK CREEK PHARMACEUTICALS, INC.	-.--%	-.--%	-	-	17.04K
ELI LILLY AND COMPANY	+0.28%	+1.73%	+63.11%	+117.65%	1,055B
JOHNSON & JOHNSON	+0.58%	+1.06%	+49.94%	+73.59%	654B
ABBVIE INC.	+0.29%	-0.20%	+18.27%	+73.36%	467B
ROCHE HOLDING AG	-1.53%	-2.66%	+38.66%	+42.21%	348B
NOVARTIS AG	+1.80%	+4.89%	+22.99%	+30.00%	275B
ASTRAZENECA PLC	+0.15%	-0.24%	+13.01%	+13.85%	258B
AMGEN INC.	+0.31%	+5.62%	+51.57%	+53.33%	224B
GILEAD SCIENCES, INC.	+0.16%	-0.46%	+33.08%	+98.71%	187B
NOVO NORDISK A/S	-0.40%	-3.15%	-28.36%	-61.35%	171B
Average	+0.12%	+0.67%	+29.14%	+49.04%	363.83B
Weighted average by Cap.	+0.18%	+1.32%	+39.52%	+69.52%

Rock Creek Pharmaceuticals, Inc. Stock

Stocks

RCPIQ

US7720812046

Pharmaceuticals

Valuation: Rock Creek Pharmaceuticals, Inc.

Latest news: Rock Creek Pharmaceuticals, Inc.

Analysts' recommendations: Rock Creek Pharmaceuticals, Inc.

Other Pharmaceuticals

Financials

Company Profile

	2014	2015
Net sales	-	-
Net income	-38.52M -33.8M -31.92M -29.09M -54.46M -3.69B -54.84M -382M -148M -1.89B -145M -141M -6.06B	-6.84M -6.01M -5.67M -5.17M -9.68M -656M -9.75M -67.88M -26.29M -335M -25.7M -25.14M -1.08B
Net Debt	-45K -39.49K -37.29K -33.99K -63.62K -4.31M -64.08K -446K -173K -2.2M -169K -165K -7.08M	19.86M 17.42M 16.46M 15M 28.07M 1.9B 28.27M 197M 76.27M 972M 74.56M 72.94M 3.12B